

**Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex)
Recombinant Antibody
Catalog # APR10972**

Specification

**Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) -
Product Information**

Application	FC, E, FTA
Primary Accession	Q8NHJ6
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG
Calculated MW	144.36 KDa

**Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) -
Additional Information**

Target/Specificity
LILRB4 / ILT3 / CD85k

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions -20°C for 1 year under sterile conditions Avoid repeated freeze-thaw cycles.

**Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) -
Protein Information**

Name LILRB4

Synonyms ILT3, LIR5

Function

Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance (PubMed:11875462). Receptor for FN1 (PubMed:34089617

Receptor for apolipoprotein APOE (PubMed:[30333625](http://www.uniprot.org/citations/30333625)). Receptor for ALCAM/CD166 (PubMed:[29263213](http://www.uniprot.org/citations/29263213)). Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:[9151699](http://www.uniprot.org/citations/9151699)). Inhibits FCGR1A/CD64-mediated monocyte activation by inducing phosphatase-mediated down-regulation of the phosphorylation of multiple proteins including LCK, SYK, LAT and ERK, leading to a reduction in TNF production (PubMed:[19833736](http://www.uniprot.org/citations/19833736)). This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:[34089617](http://www.uniprot.org/citations/34089617)). Inhibits T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells and enhancing the generation of CD8+ T suppressor cells (PubMed:[16493035](http://www.uniprot.org/citations/16493035), PubMed:[19833736](http://www.uniprot.org/citations/19833736), PubMed:[29263213](http://www.uniprot.org/citations/29263213)). Induces up-regulation of CD86 on dendritic cells (PubMed:[19860908](http://www.uniprot.org/citations/19860908)). Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation (PubMed:[11875462](http://www.uniprot.org/citations/11875462)).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment

Tissue Location


Detected on monocytes, macrophages, dendritic cells, natural killer cells and B-cells (at protein level). Expressed in the lung.


Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) - Images





Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) is more than 95% ,determined by SEC-HPLC.